ERBB2 and cholangiocarcinoma: A phase I study of 11 patients with human epidermal growth factor receptor 2 (HER2)-positive advanced CCA (n = 9) treated with HER2-targeted CAR-T therapy demonstrated disease control in 4/9 patients with CCA, which included a PR that lasted 4.5 months (109).